Gapping down
In reaction to disappointing earnings/guidance: LRN -24.1%, (also downgraded to Neutral at Robert W. Baird, downgraded to Market Perform from Outperform at BMO Capital Mkts), YUM -7% (reports China same store sales for September; revises Q4 same store sales expectations), KNX -5.8%, CAS -5.5%, FAST -5%, FDO -3.1%, COST -1.3%.
M&A news: HRB -5.7% (Republic Bancorp disclosed it is withdrawing application to merge with H&R Block).
Other news: ARIA -60.1% (Ariad Pharm announces changes in the clinical development program of iclusig; patient enrollment in all clinical studies of iclusig is being paused), CYTR -16.1% (announces proposed public offering of common stock, size not disclosed), LXRX -15.1% (completes pilot study of telotristat etiprate in Ulcerative Colitis; In this pilot study of mild to moderate ulcerative colitis, telotristat etiprate achieved the primary objective of demonstrating safety and tolerability), LPTN -9.8% (provides update on plans for iSONEP option: Pfizer (PFE) seeking to divest option for a worldwide license to develop and commercialize Isonep), CGIX -4% (files form S-1 for IPO; registration amount of $46 mln ), DYAX -3.8% (announces proposed public offering of common stock; size not disclosed), TKMR -2.8% (announced the key programs and goals into 2014 for its RNAi therapeutic product pipeline; financial guidance remains the same), ICPT -2.6% (prices 1.5 mln shares of common stock by selling shareholders at $62.50 per share), ARMH -2.4% (still checking), VISN -2.4% (modestly pulling back), SWFT -1.3% (still checking), ASML -1.1% (still checking), DEO -1% (still checking), WERN -0.6% (following KNX guidance), YGE -0.5% (Yingli Green Energy responds to Energy Conversion Devices' antitrust litigation).
Analyst comments: PSUN -2.3% (downgraded to Neutral from Overweight at Piper Jaffray), CJES -2% (Cdowngraded to Market Perform from Outperform at Cowen ), RL -0.7% (downgraded to Neutral from Overweight at Piper Jaffray), HES -0.3% (downgraded to Neutral from Buy at Citigroup)